Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib
Breakthrough Therapy Designation granted to elironrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small...
immunotherapy
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
During the year ended April 30, 2025, net cash provided by financing activities was $10.4 millionStockholder equity of $4.0 million...
Regen BioPharma, Inc. to Seek Orphan Drug Designation for Lead Product
An Orphan Drug Designation Could Provide Significant Benefits to Regen SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma,...
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
SAN DIEGO and CALGARY, AB, July 22, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a...
From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits
USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 22, 2025 /PRNewswire/ -- USA News Group...
Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd
WEXFORD, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen...
SAB BIO Announces Oversubscribed $175 Million Private Placement
Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce...
ImCheck’s Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia
ImCheck’s Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia Following the FDA ODD, European designation...
Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025
SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will...
EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK
Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has...
Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President, Research & Development
Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President,...
ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia
ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia Clinical data showing unprecedented remission rates in...
Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President, Research & Development
Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President,...
BioNTech Announces Ryan Richardson to Step Down from the Management Board
MAINZ, Germany, July 17, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Ryan...
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
Compelling new preliminary data consistent with previously reported preclinical findings demonstrating certepetide’s potential ability to enhance the effectiveness of immunotherapyBASKING...
Immuron – FY25 global sales exceed projection, up 49% on prior year
Sales Highlights (unaudited): Global Annual sales AUD$7.3 million up 49% on prior yearJune 2025 Quarter AUD$2.0 million up 55% on...
SandboxAQ and iOncologi Partner to Accelerate Brain Cancer Treatment with AI-driven Drug Discovery For Glioblastoma
This collaboration leverages AI-driven molecular design and deep tech immunotherapy expertise to advance a transformative mRNA-based treatment to the clinic...
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer
Additional complete response (CR) observed in patient with multiple tumorsConfirmed overall response rate (ORR) of 50% in patients with combined...
Immorta Bio, a Scientific Longevity Company, Appoints Pharmaceutical Industry Veteran Dr. Armin Rath as Chief Business Officer
Senolytic Immunotherapy Leader Expands Executive Team in Anticipation of Clinical Trial Launch MIAMI BEACH, Fla., July 15, 2025 /PRNewswire/ --...
PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results
Metastatic Colorectal Cancer Cohort in NCI-Led Multi-Cohort Study Demonstrates Promising Response Rate, Triggering Enrollment Expansion Under Simon Two-Stage DesignPRINCETON, N.J.,...